A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 9,828 shares of GH stock, worth $347,911. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,828
Previous 9,787 0.42%
Holding current value
$347,911
Previous $283,000 20.49%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$22.3 - $36.29 $914 - $1,487
41 Added 0.42%
9,828 $225,000
Q2 2024

Jul 26, 2024

SELL
$16.07 - $31.84 $268,240 - $531,473
-16,692 Reduced 63.04%
9,787 $283,000
Q1 2024

Apr 24, 2024

BUY
$17.13 - $26.91 $28,110 - $44,159
1,641 Added 6.61%
26,479 $546,000
Q4 2023

Feb 09, 2024

SELL
$21.58 - $29.5 $18,256 - $24,957
-846 Reduced 3.29%
24,838 $672,000
Q3 2023

Oct 24, 2023

BUY
$25.8 - $39.97 $296,648 - $459,575
11,498 Added 81.05%
25,684 $761,000
Q2 2023

Jul 13, 2023

SELL
$20.94 - $38.01 $8,229 - $14,937
-393 Reduced 2.7%
14,186 $508,000
Q1 2023

May 11, 2023

BUY
$22.92 - $33.76 $148,154 - $218,224
6,464 Added 79.65%
14,579 $342,000
Q4 2022

Feb 08, 2023

BUY
$25.44 - $59.78 $52,762 - $123,983
2,074 Added 34.33%
8,115 $221,000
Q3 2022

Oct 17, 2022

BUY
$43.66 - $61.0 $263,750 - $368,501
6,041 New
6,041 $325,000
Q1 2022

May 12, 2022

SELL
$48.25 - $100.49 $137,995 - $287,401
-2,860 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$88.71 - $120.43 $178,661 - $242,546
-2,014 Reduced 41.32%
2,860 $286,000
Q3 2021

Nov 02, 2021

BUY
$98.77 - $132.17 $13,432 - $17,975
136 Added 2.87%
4,874 $609,000
Q2 2021

Aug 10, 2021

SELL
$109.77 - $165.68 $392,317 - $592,140
-3,574 Reduced 43.0%
4,738 $588,000
Q1 2021

May 07, 2021

SELL
$127.04 - $179.1 $983,416 - $1.39 Million
-7,741 Reduced 48.22%
8,312 $1.27 Million
Q4 2020

Feb 04, 2021

BUY
$99.96 - $135.93 $763,594 - $1.04 Million
7,639 Added 90.79%
16,053 $2.07 Million
Q3 2020

Oct 29, 2020

BUY
$80.32 - $111.8 $218,470 - $304,096
2,720 Added 47.77%
8,414 $940,000
Q2 2020

Jul 27, 2020

BUY
$60.49 - $97.5 $43,855 - $70,687
725 Added 14.59%
5,694 $461,000
Q1 2020

May 08, 2020

SELL
$59.04 - $88.81 $3,424 - $5,150
-58 Reduced 1.15%
4,969 $345,000
Q4 2019

Feb 04, 2020

BUY
$59.49 - $82.78 $47,948 - $66,720
806 Added 19.1%
5,027 $392,000
Q3 2019

Nov 06, 2019

SELL
$62.59 - $110.3 $106,590 - $187,840
-1,703 Reduced 28.75%
4,221 $269,000
Q3 2019

Oct 28, 2019

BUY
$62.59 - $110.3 $370,783 - $653,417
5,924 New
5,924 $378,000
Q2 2019

Aug 15, 2019

SELL
$63.94 - $91.11 $196,295 - $279,707
-3,070 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$34.3 - $97.98 $105,300 - $300,798
3,070 New
3,070 $0

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.62B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.